{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:29:06Z","timestamp":1745386146684},"reference-count":23,"publisher":"Media Sphere Publishing House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2018]]},"DOI":"10.17116\/jnevro201811806277","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T11:49:25Z","timestamp":1540208965000},"page":"77","source":"Crossref","is-referenced-by-count":3,"special_numbering":"Vyp. 2","title":["Rate of progression of Parkinson's disease with early and delayed prescription of levodopa preparations."],"prefix":"10.17116","volume":"118","author":[{"given":"A. V.","family":"Rosinskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. E.","family":"Vasenina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. N.","family":"Khaybullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. S.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro201811806277-1","unstructured":"Levin OS, Fedorova NV. Parkinsons disease. M.: Medpress-inform; 2016. (In Russ.)"},{"key":"key-10.17116\/jnevro201811806277-2","doi-asserted-by":"crossref","unstructured":"Fox SH, Katzenschlager R, Lim S, Barton B, de Bie RM, Seppi K, Coelho M, Sampaio C. International Parkinson and movement disorder society evidence\u2010based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders. 2018 Mar 23. Epub ahead of print. https:\/\/doi.org\/10.1002\/mds.27372","DOI":"10.1002\/mds.27372"},{"key":"key-10.17116\/jnevro201811806277-3","doi-asserted-by":"crossref","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-844. https:\/\/doi.org\/10.1136\/jnnp-2013-306787","DOI":"10.1136\/jnnp-2013-306787"},{"key":"key-10.17116\/jnevro201811806277-4","doi-asserted-by":"crossref","unstructured":"Worth P. Results of the early stage PD MED study: revelation or recapitulation? Practical Neurology. 2015;15:408-410. https:\/\/doi.org\/10.1136\/practneurol-2015-001149","DOI":"10.1136\/practneurol-2015-001149"},{"key":"key-10.17116\/jnevro201811806277-5","doi-asserted-by":"crossref","unstructured":"Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's Disease: Current Status and Future Developments. Current Neuropharmacology. Epub ahead of print. https:\/\/doi.org\/10.2174\/1570159X15666170510143821","DOI":"10.2174\/1570159X15666170510143821"},{"key":"key-10.17116\/jnevro201811806277-6","doi-asserted-by":"crossref","unstructured":"Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. https:\/\/doi.org\/10.1212\/wnl.17.5.427","DOI":"10.1212\/WNL.17.5.427"},{"key":"key-10.17116\/jnevro201811806277-7","doi-asserted-by":"crossref","unstructured":"Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, Pica EC, Li SC, Luo N, Tan LC. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Movement Disorders. 2010;25(6):710-716. https:\/\/doi.org\/10.1002\/mds.22875","DOI":"10.1002\/mds.22875"},{"key":"key-10.17116\/jnevro201811806277-8","doi-asserted-by":"crossref","unstructured":"Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders. 2007;22(1):41-47. https:\/\/doi.org\/10.1002\/mds.21198","DOI":"10.1002\/mds.21198"},{"key":"key-10.17116\/jnevro201811806277-9","doi-asserted-by":"crossref","unstructured":"McRae C, Diem G, Vo A, O'Brien C, Seeberger L. Schwab & England: Standardization of administration. Movement Disorders. 2000;15:335-336.","DOI":"10.1002\/1531-8257(200003)15:2<335::AID-MDS1022>3.0.CO;2-V"},{"key":"key-10.17116\/jnevro201811806277-10","doi-asserted-by":"crossref","unstructured":"Cognitive assessment, the Folstein Mini-Mental State Examination (MMSE). Clinical Skills for OSCEs: Second Edition; 2006. https:\/\/doi.org\/10.1201\/b17661-53","DOI":"10.1201\/b17661-53"},{"key":"key-10.17116\/jnevro201811806277-11","doi-asserted-by":"crossref","unstructured":"Manos P. The ten-point clock test: a quick screen for cognitive impairment in medical and surgical patients. The American Journal of Geriatric Psychiatry. 1994;7:49. https:\/\/doi.org\/10.1097\/00019442-199911001-00142","DOI":"10.1097\/00019442-199911001-00142"},{"key":"key-10.17116\/jnevro201811806277-12","doi-asserted-by":"crossref","unstructured":"Glozman JM. Quantitative and qualitative integration of Lurian procedures. Neuropsychol Rev. 1999;9:23. https:\/\/doi.org\/10.1023\/A:1025638903874","DOI":"10.1023\/A:1025638903874"},{"key":"key-10.17116\/jnevro201811806277-13","doi-asserted-by":"crossref","unstructured":"Beck C, Gable R. Postpartum Depression Screening Scale: Development and Psychometric Testing. Nursing Research. 2000;49(5):272-282. https:\/\/doi.org\/10.1097\/00006199-200009000-00006","DOI":"10.1097\/00006199-200009000-00006"},{"key":"key-10.17116\/jnevro201811806277-14","doi-asserted-by":"crossref","unstructured":"Starkstein S. Apathy in Parkinson's disease: Diagnostic and etiological dilemmas. Movement Disorders. 2012;27(2):174-178. https:\/\/doi.org\/10.1002\/mds.24061","DOI":"10.1002\/mds.24061"},{"key":"key-10.17116\/jnevro201811806277-15","doi-asserted-by":"crossref","unstructured":"Espay AJ, Lang AE. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. JAMA Neurol. 2017;74(6):633-634. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0348","DOI":"10.1001\/jamaneurol.2017.0348"},{"key":"key-10.17116\/jnevro201811806277-16","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study. Clinical Neuropharmacology. 2000;23(1):34-44. https:\/\/doi.org\/10.1097\/00002826-200001000-00007","DOI":"10.1097\/00002826-200001000-00007"},{"key":"key-10.17116\/jnevro201811806277-17","doi-asserted-by":"crossref","unstructured":"Whone A, Watts R, Stoessl A, Davis M, Reske S, Nahmias C, Lang A, Rascol O, Ribeiro M, Remy P, Poewe W, Hauser R, Brooks D. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology. 2003;54(1):93-101. https:\/\/doi.org\/10.1002\/ana.10609","DOI":"10.1002\/ana.10609"},{"key":"key-10.17116\/jnevro201811806277-18","doi-asserted-by":"crossref","unstructured":"Zhang J, Tan LC-S. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. Current Neuropharmacology. 2016;14(4):356-363. https:\/\/doi.org\/10.2174\/1570159X14666151208114634","DOI":"10.2174\/1570159X14666151208114634"},{"key":"key-10.17116\/jnevro201811806277-19","doi-asserted-by":"crossref","unstructured":"Mostile G, Nicoletti A, Dibilio V, Luca A, Raciti L, Sciacca G, Cicero C, Vasta R, Donzuso G, Contrafatto D, Zappia M. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson\u02bcs Disease. European Journal of Neurology. 2014;21(1)104-387. https:\/\/doi.org\/10.1097\/wnf.0000000000000186","DOI":"10.1097\/WNF.0000000000000186"},{"key":"key-10.17116\/jnevro201811806277-20","doi-asserted-by":"crossref","unstructured":"Antonini A, Fung V, Boyd J, Slevin J, Hall C, Chatamra K, Eaton S, Benesh J. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Movement Disorders. 2016;31(4):530-537. https:\/\/doi.org\/10.1002\/mds.26528","DOI":"10.1002\/mds.26528"},{"key":"key-10.17116\/jnevro201811806277-21","doi-asserted-by":"crossref","unstructured":"Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Movement Disorders. 2015;30:80-89. https:\/\/doi.org\/10.1002\/mds.26125","DOI":"10.1002\/mds.26125"},{"key":"key-10.17116\/jnevro201811806277-22","doi-asserted-by":"crossref","unstructured":"Yao Z, Shao Y, Han X. Freezing of gait is associated with cognitive impairment in patients with Parkinson disease. Neuroscience Letters. 2017;656:126-130. https:\/\/doi.org\/10.1016\/j.neulet.2017.07.004","DOI":"10.1016\/j.neulet.2017.07.004"},{"key":"key-10.17116\/jnevro201811806277-23","doi-asserted-by":"crossref","unstructured":"Peterson DS, King LA, Cohen RG, Horak FB; Cognitive Contributions to Freezing of Gait in Parkinson Disease: Implications for Physical Rehabilitation. Physical Therapy. 2016;96(5):659-670. https:\/\/doi.org\/10.2522\/ptj.20140603","DOI":"10.2522\/ptj.20140603"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T12:14:42Z","timestamp":1572178482000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2018\/6\/downloads\/ru\/1199772982018062077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"alternative-id":["jnevro201811806277"],"URL":"https:\/\/doi.org\/10.17116\/jnevro201811806277","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}